Dyno founder and CEO Eric Kelsic stated: “This new collaboration with Roche, focused on developing next-generation gene ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering ...

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

Roche Holding AG is willing to pay more than $1 billion to solve one of the biggest challenges of gene therapy: delivery.

New strategic partnership leverages the power of Dyno’s platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets ...

US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research ...

This week, Johnson & Johnson JNJ began the third-quarter earnings season for the drug and biotech sector. The FDA granted ...

Sunir Garg, MD, shares insights on new data on aflibercept 8 mg, faricimab, and the impact of social determinants of health, ...

Consumer groups and labor unions have asked the FTC to block Novo Holdings' acquisition of Catalent due to competition ...